Centessa Pharmaceuticals PLC ADR (CNTA NASDAQ) stock market data APIs
$39.6444
0.03(0.1%)
as of May 6, 2026
Try our APIs with
free plan!
Centessa Pharmaceuticals PLC ADR Financial Data Overview
Price chart is built with
Anychart
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Prev. Close
39.6444
Open
39.6739
High
39.677
Low
39.6108
52 wk Range
10.95-40.26
Market Cap
6 127 M
Shares Outstanding
155 M
EPS
-0.48
Beta
1.14
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Centessa Pharmaceuticals PLC ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Centessa Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Centessa Pharmaceuticals PLC ADR Fundamental Data
Centessa Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -256 344 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Centessa Pharmaceuticals PLC ADR Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-26
- EPS/Forecast: -0.3843
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Centessa Pharmaceuticals PLC ADR News
New
Eli Lilly Sells $9 Billion of Bonds to Fund Acquisitions
(Bloomberg) -- Eli Lilly & Co. sold $9 billion of investment-grade bonds Wednesday — the company’s biggest-ever issuance — as it looks to finance an acquisition spree. Most Read from Bloomberg ...
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. For investors wondering if Centessa Pharmaceuticals at arou...
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
Eli Lilly and Company LLY reported first-quarter 2026 adjusted earnings per share (“EPS”) of $8.55, which comprehensively beat the Zacks Consensus Estimate of $7.06 per share. Earnings rose 156% y...
Get Centessa Pharmaceuticals PLC ADR fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
